- NYSE:PFE gains 0.22% as broader markets continue to rally on Tuesday.
- Biotech giant AstraZeneca announces its COVID-19 vaccine candidate as the ‘vaccine for the world’.
- Regeneron also receives emergency use authorization from the FDA.
NYSE:PFE has not performed as one would imagine a stock would after announcing a high efficacy rate for one of the most important vaccines in our lifetime. The stock has traded down since the announcement on November 9th, and despite an initial pop shortly afterwards, shares have lost 5% since. On Tuesday, the stock gained a meager 0.22% to close the trading session at $36.60. Pfizer’s partner BioNTech (NASDAQ:BNTX) has experienced an even lower drop as the German biotech firm has seen its stock fall by 11% since the vaccine was announced.
Just as the news of Pfizer providing its first 6.4 million doses by mid-December was released, several other biotech players entered the COVID-19 vaccine discussion. British giant AstraZeneca (NASDAQ:AZN) reported that it is awaiting the final results of its late-stage clinical trials, and could potentially be able to provide limited quantities of its vaccine candidate by the end of the year. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) also entered the fray as its antibody cocktail, made famous by President Trump, was granted EUA or emergency use authorization by the FDA.
PFE stock quote
We knew that Pfizer would not be the only dog in this fight, but thus far, the New York-based pharmaceutical titan has proven to have the highest efficacy rate in its proposed vaccine. What does this mean for Pfizer’s stock? It should remain steady in the meantime as even world-changing announcements have little effect on its price. With a solid dividend yield of 4.16%, it would not be the worst idea to take a small position in Pfizer, as it could be in for a profitable 2021.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
AUD/USD: The hunt for the 0.7000 hurdle
AUD/USD quickly left behind Wednesday’s strong pullback and rose markedly past the 0.6900 barrier on Thursday, boosted by news of fresh stimulus in China as well as renewed weakness in the US Dollar.
EUR/USD refocuses its attention to 1.1200 and above
Rising appetite for the risk-associated assets, the offered stance in the Greenback and Chinese stimulus all contributed to the resurgence of the upside momentum in EUR/USD, which managed to retest the 1.1190 zone on Thursday.
Gold holding at higher ground at around $2,670
Gold breaks to new high of $2,673 on Thursday. Falling interest rates globally, intensifying geopolitical conflicts and heightened Fed easing bets are the main factors.
Bitcoin displays bullish signals amid supportive macroeconomic developments and growing institutional demand
Bitcoin (BTC) trades slightly up, around $64,000 on Thursday, following a rejection from the upper consolidation level of $64,700 the previous day. BTC’s price has been consolidating between $62,000 and $64,700 for the past week.
RBA widely expected to keep key interest rate unchanged amid persisting price pressures
The Reserve Bank of Australia is likely to continue bucking the trend adopted by major central banks of the dovish policy pivot, opting to maintain the policy for the seventh consecutive meeting on Tuesday.
Five best Forex brokers in 2024
VERIFIED Choosing the best Forex broker in 2024 requires careful consideration of certain essential factors. With the wide array of options available, it is crucial to find a broker that aligns with your trading style, experience level, and financial goals.